Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Traws Pharma, Inc./ DEFA14A

SEC Filing · DEFA14A

Traws Pharma, Inc.

SEC Filing

Filed Oct 20, 2026Accepted Oct 20, 2026, 4:09 PM EDTCIK 1130598Accession 0001104659-26-117414
View company →Permanent SEC source ↗
Share

Company context

Pharma, Inc. Traws Pharma is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to meet real world challenges in the treatment of viral diseases. The Company is advancing novel investigational oral small molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health including seasonal influenza and H5N1 bird flu, negative-strand RNA viruses including Hantavirus, Ebola Virus Disease, Lassa Fever and COVID-19/Long COVID.

Current securities

ONXXFOTC · EQUITY · CurrentONXYYOTC · ADR · CurrentTRAWNASDAQ · EQUITY · Current
Historical securities (3)
ONTXOTC · EQUITY · Historical · closed Jul 26, 2021ONTXWNASDAQ · WARRANT · Historical · closed Jul 23, 2021TRAWNASDAQ · EQUITY · Historical · closed Oct 19, 2026

Recent company filings

  1. S-1 filingOct 26, 2026
  2. Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesOct 23, 2026
  3. DEF 14A filingOct 20, 2026
  4. PRE 14A filingOct 8, 2026
  5. SCHEDULE 13G/A - filed by Ikarian Capital, LLC regarding Traws Pharma, Inc.Aug 14, 2026

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.